PFKFB4 and hepatoblastoma: In this study, we identified dual overexpression of PFKFB4 and DNMT3B in hepatoblastoma patient samples with metastatic risk (high-risk CHIC stratification), based on the metabolic enzyme expression program of hepatoblastoma tumors.